AltMountain

N2C Derm & Pain LP

New York, NY · CIK 1771266
Status: no Form D since Apr 2019. Funds file a Form D when they begin selling and amend it each year while the offering continues, so this fund has most likely stopped raising money. It may still be investing, or it may have closed or been dissolved. The details below are from its latest filing, kept here as a record.

N2C Derm & Pain LP is a private equity fund based in New York, New York. According to its most recent Form D, filed Apr 4, 2019, it has sold $42,100,000 of interests to 3 investors since its first sale in Feb 2019. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Tjarko Hektor; Dan Townsend; Clay Cole.

Total raised
$42,100,000Cumulative sales reported on Form D
Investors
3
First sale
Feb 26, 2019
Minimum investment
None set
Who can invest
Qualified purchasersSection 3(c)(7): generally $5M+ in investments
Offering exemption
Rule 506(b)No general advertising
Key people and entities
Tjarko Hektor; Dan Townsend; Clay Cole
Latest Form D
Apr 4, 2019

From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠

Questions about N2C Derm & Pain LP

What is the minimum investment for N2C Derm & Pain LP?

N2C Derm & Pain LP's latest Form D, filed Apr 4, 2019, does not set a minimum investment. Managers can still require one in the offering documents.

Who can invest in N2C Derm & Pain LP?

N2C Derm & Pain LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.

How much has N2C Derm & Pain LP raised?

N2C Derm & Pain LP reports $42,100,000 sold from 3 investors on its Form D filed Apr 4, 2019. This is cumulative sales since the offering began, not current assets or performance.

Where is N2C Derm & Pain LP based?

N2C Derm & Pain LP is based in New York, New York.

When did N2C Derm & Pain LP launch?

N2C Derm & Pain LP reports its first sale in Feb 2019.

Size compared with every private equity fund

Raised more than 69% of the 3,670 private equity funds based in New York, and more than 61% of all 8,975 that report sales.

Other funds with the same team

More private equity funds in New York

Similar-size private equity funds in New York

All private equity funds in New York